Abstract 17924: Bivalirudin versus Heparin in Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation: A Multicenter Propensity-Matched Analysis
Abstract
Background: Patients undergoing veno-arterial extracorporeal membrane oxygenation (VA-ECMO) require systemic anticoagulation but remain at high risk for bleeding and thrombotic complications. Unfractionated heparin is commonly used, while bivalirudin has emerged as an alternative; however, comparative real-world outcome data remain limited. We evaluated short-term outcomes associated with bivalirudin versus heparin among adults undergoing VA-ECMO. Methods: We performed a retrospective cohort study using the TriNetX US Collaborative Network. Adults aged ≥18 years who underwent VA-ECMO between January 1, 2015 and April 30, 2025 and received bivalirudin or heparin within 3 days of ECMO initiation were identified. Patients were compared after 1:1 propensity score matching for demographics, comorbidities, markers of illness severity, vasopressor use, antiplatelet therapy, and baseline laboratory parameters. Outcomes were assessed from day 3 through day 14 after ECMO initiation. Time-to-event outcomes were assessed using Kaplan-Meier analysis and hazard ratios were estimated using Cox proportional hazards regression. Outcomes included all-cause mortality, bleeding composite (hemoptysis, melena, hematemesis, other gastrointestinal bleeding or intracranial hemorrhage), blood product transfusion, ECMO-related/postprocedural hemorrhage, and thrombotic composite (cerebral infarction, intracardiac thrombosis, pulmonary embolism, or acute extremity embolism). Results: Before matching, 1,178 patients received bivalirudin and 5,278 received heparin. After propensity score matching, 1,158 patients were included in each group. All-cause mortality did not differ significantly between bivalirudin and heparin groups (22.6% vs 24.1%; HR 0.92, 95% CI 0.78-1.09; p=0.339). The bleeding composite was also similar between groups (HR 1.05, 95% CI 0.86-1.29; p=0.603). Bivalirudin was associated with a lower hazard of transfusion (20.5% vs 26.1%; HR 0.76, 95% CI 0.64-0.90; p=0.001), but a higher hazard of ECMO-related/postprocedural hemorrhage (4.6% vs 2.7%; HR 1.71, 95% CI 1.10-2.66; p=0.017). There were no significant differences in thrombotic events (HR 1.11, 95% CI 0.91-1.35; p=0.306). Conclusion: In this large multicenter propensity-matched cohort of adults undergoing VA-ECMO, bivalirudin and heparin were associated with similar short-term mortality, bleeding composite, and thrombotic events. Bivalirudin was associated with lower transfusion hazard but higher ECMO-related/postprocedural hemorrhage, highlighting a nuanced safety profile that warrants further prospective evaluation.